Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
28
10
2022
accepted:
12
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
epublish
Résumé
Antimicrobial resistance is a global health threat that requires the development of new treatment concepts. These should not only overcome existing resistance but be designed to slow down the emergence of new resistance mechanisms. Targeted protein degradation, whereby a drug redirects cellular proteolytic machinery towards degrading a specific target, is an emerging concept in drug discovery. We are extending this concept by developing proteolysis targeting chimeras active in bacteria (BacPROTACs) that bind to ClpC1, a component of the mycobacterial protein degradation machinery. The anti-Mycobacterium tuberculosis (Mtb) BacPROTACs are derived from cyclomarins which, when dimerized, generate compounds that recruit and degrade ClpC1. The resulting Homo-BacPROTACs reduce levels of endogenous ClpC1 in Mycobacterium smegmatis and display minimum inhibitory concentrations in the low micro- to nanomolar range in mycobacterial strains, including multiple drug-resistant Mtb isolates. The compounds also kill Mtb residing in macrophages. Thus, Homo-BacPROTACs that degrade ClpC1 represent a different strategy for targeting Mtb and overcoming drug resistance.
Identifiants
pubmed: 38443338
doi: 10.1038/s41467-024-46218-7
pii: 10.1038/s41467-024-46218-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2005Informations de copyright
© 2024. The Author(s).
Références
Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
doi: 10.1016/S0140-6736(21)02724-0
Roope, L. S. J. et al. The challenge of antimicrobial resistance: What economics can contribute. Science 364, eaau4679 (2019).
doi: 10.1126/science.aau4679
Jit, M. et al. Quantifying the economic cost of antibiotic resistance and the impact of related interventions: Rapid methodological review, conceptual framework and recommendations for future studies. BMC Med. 18, 1–14 (2020).
doi: 10.1186/s12916-020-1507-2
Cook, M. A. & Wright, G. D. The past, present, and future of antibiotics. Sci. Transl. Med. 14, eabo7793 (2022).
doi: 10.1126/scitranslmed.abo7793
Plackett, B. No money for new drugs. Nat. Outlook 586, 50–52 (2020).
Kurt Yilmaz, N. & Schiffer, C. A. Introduction: Drug resistance. Chem. Rev. 121, 3235–3237 (2021).
doi: 10.1021/acs.chemrev.1c00118
Chifiriuc, M. C. et al. Common themes in antimicrobial and anticancer drug resistance. Front Microbiol. 13, 1–12 (2022).
doi: 10.3389/fmicb.2022.960693
Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
doi: 10.1038/s41573-021-00371-6
Ciulli, A. & Trainor, N. A beginner’s guide to PROTACs and targeted protein degradation. Biochemist 43, 74–79 (2021).
doi: 10.1042/bio_2021_148
Paiva, S. L. & Crews, C. M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 50, 111–119 (2019).
doi: 10.1016/j.cbpa.2019.02.022
Maniaci, C. et al. Homo-PROTACs: Bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat. Commun. 8, 830 (2017).
doi: 10.1038/s41467-017-00954-1
Steinebach, C. et al. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem. Biol. 13, 2771–2782 (2018).
doi: 10.1021/acschembio.8b00693
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
doi: 10.1038/s41586-020-2545-9
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
doi: 10.1038/s41589-021-00770-1
Alabi, S. B. & Crews, C. M. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, 100647 (2021).
doi: 10.1016/j.jbc.2021.100647
Mares, A. et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol. 3, 1–13 (2020).
doi: 10.1038/s42003-020-0868-6
Guenette, R. G., Yang, S. W., Min, J., Pei, B. & Potts, P. R. Target and tissue selectivity of PROTAC degraders. Chem. Soc. Rev. 51, 5740–5756 (2022).
doi: 10.1039/D2CS00200K
Burke, M. R., Smith, A. R. & Zheng, G. Overcoming cancer drug resistance utilizing PROTAC technology. Front Cell Dev. Biol. 10, 1–22 (2022).
doi: 10.3389/fcell.2022.872729
Trentini, D. B. et al. Arginine phosphorylation marks proteins for degradation by a Clp protease. Nature 539, 48–53 (2016).
doi: 10.1038/nature20122
Morreale, F. E. et al. BacPROTACs mediate targeted protein degradation in bacteria. Cell 185, 2338–2353 (2022).
doi: 10.1016/j.cell.2022.05.009
Global Tuberculosis Report. (World Health Organization, 2020).
Pai, M., Kasaeva, T. & Swaminathan, S. Covid-19’s devastating effect on tuberculosis Care - A path to recovery. N. Engl. J. Med. 386, 1490–1493 (2022).
doi: 10.1056/NEJMp2118145
Global Tuberculosis Report. (World Health Organization, 2021).
Vasudevan, D., Rao, S. P. S. & Noble, C. G. Structural basis of mycobacterial inhibition by Cyclomarin A. J. Biol. Chem. 288, 30883–30891 (2013).
doi: 10.1074/jbc.M113.493767
Wolf, N. M. et al. High-resolution structure of ClpC1-Rufomycin and ligand binding studies provide a framework to design and optimize anti-tuberculosis leads. ACS Infect. Dis. 5, 829–840 (2019).
doi: 10.1021/acsinfecdis.8b00276
Gavrish, E. et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem. Biol. 21, 509–518 (2014).
doi: 10.1016/j.chembiol.2014.01.014
Gao, W. et al. The cyclic peptide ecumicin targeting CLpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 59, 880–889 (2015).
doi: 10.1128/AAC.04054-14
Wolf, N. M. et al. Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions. Acta Crystallogr. D. Struct. Biol. 76, 458–471 (2020).
doi: 10.1107/S2059798320004027
Kiefer, A. et al. Synthesis of New Cyclomarin derivatives and their biological evaluation towards mycobacterium tuberculosis and Plasmodium Falciparum. Chem. - Eur. J. 1, 8894–8902 (2019).
doi: 10.1002/chem.201901640
Junk, L., Papadopoulos, E., Kazmaier, U. & Tryptophan, N. 1-Alkylation: Quick and simple access to diversely substituted tryptophans. Synthesis 53, 2503–2511 (2021).
doi: 10.1055/a-1404-5079
Abraham, M. H. et al. An NMR method for the quantitative assessment of intramolecular hydrogen bonding; Application to physicochemical, environmental, and biochemical properties. J. Org. Chem. 79, 11075–11083 (2014).
doi: 10.1021/jo502080p
Cierpicki, T. & Otlewski, J. Amide proton temperature coefficients as hydrogen bond indicators in proteins. J. Biomol. NMR 21, 249–261 (2001).
doi: 10.1023/A:1012911329730
Otake, Y. et al. N‐methylated peptide synthesis via generation of an Acyl N‐methylimidazolium cation accelerated by a Brønsted acid. Angew. Chem. 132, 13025–13030 (2020).
doi: 10.1002/ange.202002106
Hoi, D. M. et al. Development of a dual Clp-targeting BacPROTAC that impairs mycobacterial proteostasis and survival. Cell 186, 2176–2192 (2023).
doi: 10.1016/j.cell.2023.04.009
Meena, L. S. & Rajni, T. Survival mechanisms of pathogenic Mycobacterium tuberculosis H 37Rv. FEBS J. 277, 2416–2427 (2010).
doi: 10.1111/j.1742-4658.2010.07666.x
Peddireddy, V., Doddam, S. N. & Ahmed, N. Mycobacterial dormancy systems and host responses in tuberculosis. Front. Immunol. 8, 84 (2017).
doi: 10.3389/fimmu.2017.00084
Leodolter, J., Warweg, J. & Weber-Ban, E. The Mycobacterium tuberculosis ClpP1P2 protease interacts asymmetrically with its ATPase partners ClpX and ClpC1. PLoS One 10, 1–21 (2015).
doi: 10.1371/journal.pone.0125345
Kaur, P. et al. A high-throughput cidality screen for Mycobacterium tuberculosis. PLoS One 10, 1–13 (2015).
doi: 10.1371/journal.pone.0117577
Shirude, P. S. et al. Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J. Med. Chem. 56, 9701–9708 (2013).
doi: 10.1021/jm401382v
Rouse, D. A. & Morris, S. L. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect. Immun. 63, 1427–1433 (1995).
doi: 10.1128/iai.63.4.1427-1433.1995
Garcia, L., Alonso-Sanz, M., Rebollo, M. J., Tercero, J. C. & Chaves, F. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis isolates in Spain and their rapid detection by PCR-enzyme-linked immunosorbent assay. J. Clin. Microbiol. 39, 1813–1818 (2001).
doi: 10.1128/JCM.39.5.1813-1818.2001